NO970939L - Fremgangsmåte ved fremstilling av paroksetinhydrokloridanhydrat - Google Patents

Fremgangsmåte ved fremstilling av paroksetinhydrokloridanhydrat

Info

Publication number
NO970939L
NO970939L NO970939A NO970939A NO970939L NO 970939 L NO970939 L NO 970939L NO 970939 A NO970939 A NO 970939A NO 970939 A NO970939 A NO 970939A NO 970939 L NO970939 L NO 970939L
Authority
NO
Norway
Prior art keywords
preparation
paroxetine hydrochloride
hydrochloride anhydrate
anhydrate
paroxetine
Prior art date
Application number
NO970939A
Other languages
English (en)
Other versions
NO311519B1 (no
NO970939D0 (no
Inventor
Victor Witold Jacewicz
Neal Ward
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27267578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO970939(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9502297.6A external-priority patent/GB9502297D0/en
Priority claimed from GBGB9503112.6A external-priority patent/GB9503112D0/en
Priority claimed from GBGB9509807.5A external-priority patent/GB9509807D0/en
Publication of NO970939L publication Critical patent/NO970939L/no
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO970939D0 publication Critical patent/NO970939D0/no
Publication of NO311519B1 publication Critical patent/NO311519B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO19970939A 1995-02-06 1997-02-28 Fremgangsmåte ved fremstilling av paroksetinhydrokloridanhydrat NO311519B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9502297.6A GB9502297D0 (en) 1995-02-06 1995-02-06 Novel compound
GBGB9503112.6A GB9503112D0 (en) 1995-02-17 1995-02-17 Novel compound
GBGB9509807.5A GB9509807D0 (en) 1995-05-15 1995-05-15 Novel compounds

Publications (3)

Publication Number Publication Date
NO970939L true NO970939L (no) 1996-08-07
NO970939D0 NO970939D0 (no) 1997-02-28
NO311519B1 NO311519B1 (no) 2001-12-03

Family

ID=27267578

Family Applications (3)

Application Number Title Priority Date Filing Date
NO960472A NO301009B1 (no) 1995-02-06 1996-02-05 Paroksetinhydrokloridanhydrat
NO19970939A NO311519B1 (no) 1995-02-06 1997-02-28 Fremgangsmåte ved fremstilling av paroksetinhydrokloridanhydrat
NO20015070A NO20015070D0 (no) 1995-02-06 2001-10-18 Paroksetin-hydroklorid-anhydrat

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO960472A NO301009B1 (no) 1995-02-06 1996-02-05 Paroksetinhydrokloridanhydrat

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20015070A NO20015070D0 (no) 1995-02-06 2001-10-18 Paroksetin-hydroklorid-anhydrat

Country Status (47)

Country Link
EP (3) EP0808314B1 (no)
JP (2) JP2915338B2 (no)
KR (1) KR100289885B1 (no)
CN (3) CN1289496C (no)
AR (2) AR001982A1 (no)
AT (1) AT407528B (no)
AU (2) AU701518C (no)
BE (1) BE1009112A3 (no)
BG (1) BG62967B1 (no)
BR (1) BR9600534A (no)
CA (4) CA2210023C (no)
CH (3) CH688353A5 (no)
CZ (1) CZ297171B6 (no)
DE (3) DE69631298T2 (no)
DK (2) DK11996A (no)
DZ (1) DZ1989A1 (no)
ES (1) ES2114471B1 (no)
FI (3) FI111544B (no)
FR (1) FR2730232B1 (no)
GR (1) GR1002466B (no)
HK (1) HK59397A (no)
HU (1) HUP9600255A1 (no)
IE (1) IE80500B1 (no)
IL (1) IL117035A (no)
IT (1) IT1289532B1 (no)
LU (1) LU88711A1 (no)
LV (1) LV11618B (no)
MA (1) MA23802A1 (no)
MC (1) MC2411A1 (no)
MX (1) MX9600484A (no)
MY (1) MY132529A (no)
NL (1) NL1002248C2 (no)
NO (3) NO301009B1 (no)
NZ (1) NZ280943A (no)
OA (1) OA10261A (no)
PL (1) PL189247B1 (no)
PT (1) PT101827B (no)
RO (1) RO112426B1 (no)
RU (1) RU2125052C1 (no)
SE (1) SE521084C2 (no)
SG (1) SG43787A1 (no)
SI (2) SI21923B (no)
SK (1) SK283608B6 (no)
TR (1) TR199600096A2 (no)
TW (1) TW503238B (no)
UA (1) UA49796C2 (no)
WO (1) WO1996024595A1 (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3882224B2 (ja) 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
DE69739561D1 (de) 1996-06-13 2009-10-15 Sumitomo Chemical Co Piperidin Derivative als Zwischenprodukte zur Herstellung von Paroxetine und Verfahren zu ihrer Herstellung
WO1998002556A2 (en) * 1996-07-15 1998-01-22 Smithkline Beecham Plc Screening for and use of an esterase for a stereospecific resolution
US5672612A (en) * 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
CA2193939C (en) * 1996-12-24 2002-02-12 K.S. Keshava Murthy Useful form of anhydrous paroxetine hydrochloride
KR100543614B1 (ko) * 1997-06-10 2006-01-20 신톤 비.브이. 4-페닐피페리딘 화합물
ES2150808T3 (es) * 1997-08-08 2000-12-01 Aventis Pharma Gmbh Forma cristalina de (4-trifluorometil)-anilida de acido 5-metilisoxazol-4-carboxilico.
GB9726907D0 (en) * 1997-12-19 1998-02-18 Smithkline Beecham Plc Novel compounds
CA2323896A1 (en) * 1998-03-16 1999-09-23 Andrew Simon Craig Crystalline form of paroxetine
GB9806312D0 (en) * 1998-03-24 1998-05-20 Smithkline Beecham Plc Novel formulations
US6699882B2 (en) 1998-03-24 2004-03-02 Smithkline Beecham P.L.C. Paroxetine compositions
AU2003200534B2 (en) * 1998-03-24 2004-12-02 Smithkline Beecham Plc Paroxetine compositions
JP3796351B2 (ja) * 1998-04-13 2006-07-12 住友化学株式会社 パロキセチン塩酸塩無水和物の乾燥方法
GB9812941D0 (en) * 1998-06-16 1998-08-12 Smithkline Beecham Plc Method of treatment
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2138937B1 (es) 1998-07-07 2000-10-01 Medichem Sa Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen.
PT1100796E (pt) * 1998-08-07 2003-09-30 Smithkline Beecham Plc Processo para a preparacao de um cloridrato de paroxetina na forma anidra nao cristalina
GB9824298D0 (en) * 1998-11-05 1998-12-30 Smithkline Beecham Plc Novel process
GB9826175D0 (en) * 1998-11-28 1999-01-20 Smithkline Beecham Plc Novel process
GB9826176D0 (en) * 1998-11-28 1999-01-20 Smithkline Beecham Plc Novel process
GB9826242D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
ES2211232T3 (es) * 1998-11-30 2004-07-01 Smithkline Beecham Plc Solvatos mixtos de paroxetina-propan-2-ol.
GB9826178D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9826180D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9826171D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel compounds
GB9828767D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
WO2000054775A1 (de) * 1999-03-12 2000-09-21 Basf Ag Stabile pharmazeutische anwendungsform für paroxetin-anhydrat
GB9914585D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
GB9914583D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
GB9919001D0 (en) * 1999-08-12 1999-10-13 Smithkline Beecham Plc Novel process
GB9923446D0 (en) * 1999-10-04 1999-12-08 Smithkline Beecham Plc Novel process
GB9923439D0 (en) * 1999-10-04 1999-12-08 Smithkline Beecham Plc Novel process
GB9923445D0 (en) * 1999-10-04 1999-12-08 Smithkline Beecham Plc Novel process
HU226912B1 (en) * 2000-04-07 2010-03-01 Richter Gedeon Nyrt New paroxetin salt and medicament containing it
JPWO2002022609A1 (ja) * 2000-09-14 2004-01-22 旭硝子株式会社 実質的に有機溶媒を含まないパロキセチン塩類の製造方法
AU2002259114A1 (en) * 2002-02-22 2003-09-09 Teva Pharmaceutical Industries Ltd. Preparation of paroxetine involving novel intermediates
WO2007062147A1 (en) * 2005-11-22 2007-05-31 Teva Pharmaceutical Industries Ltd. Crystal forms of cinacalcet hci and processes for their preparation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
DE3688827T2 (de) * 1985-10-25 1994-03-31 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel.
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
DK715988D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Etherifikation og dealkylering af piperidin-derivater samt intermediater
DK716088D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Reduktion af piperidin-dion-derivater samt intermediat
KR930702000A (ko) * 1990-11-24 1993-09-08 데이빗 로버츠 노년기 치매, 식용항진, 편두통, 또는 식용불량의 치료를 위한 파로세틴의 사용
GB9325644D0 (en) * 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation

Also Published As

Publication number Publication date
ES2114471B1 (es) 1999-08-16
CA2210022A1 (en) 1996-08-07
NO20015070D0 (no) 2001-10-18
TW503238B (en) 2002-09-21
JPH11228571A (ja) 1999-08-24
MX9600484A (es) 1997-01-31
DE69621777D1 (de) 2002-07-18
MA23802A1 (fr) 1996-10-01
NO960472D0 (no) 1996-02-05
HUP9600255A1 (en) 1997-03-28
DE19603797A1 (de) 1996-08-14
FI111544B (fi) 2003-08-15
NO20015070L (no) 1996-08-07
DK200100223A (no) 2001-02-12
FR2730232A1 (fr) 1996-08-09
FI960519A (fi) 1996-08-07
CA2210023C (en) 1999-02-09
GR1002466B (el) 1996-11-06
DE69631298D1 (de) 2004-02-12
LV11618A (lv) 1996-12-20
SI9600036B (sl) 2006-12-31
NO311519B1 (no) 2001-12-03
CZ32096A3 (en) 1996-08-14
AR036856A2 (es) 2004-10-06
NL1002248A1 (nl) 1996-08-06
EP1378508A1 (en) 2004-01-07
ITMI960203A1 (it) 1997-08-05
PT101827B (pt) 1997-08-29
MC2411A1 (fr) 1996-12-02
MY132529A (en) 2007-10-31
KR960031409A (ko) 1996-09-17
CA2168829C (en) 1997-12-16
RU2125052C1 (ru) 1999-01-20
ES2114471A1 (es) 1998-05-16
AR001982A1 (es) 1998-01-07
IL117035A (en) 2000-02-29
CN1636993A (zh) 2005-07-13
DK11996A (da) 1996-08-07
DZ1989A1 (fr) 2002-10-15
CN1143643A (zh) 1997-02-26
FI960519A0 (fi) 1996-02-05
IT1289532B1 (it) 1998-10-15
HU9600255D0 (en) 1996-03-28
SG43787A1 (en) 1997-11-14
CN1090187C (zh) 2002-09-04
NO301009B1 (no) 1997-09-01
FI20030370A (fi) 2003-03-12
CH689229A5 (de) 1998-12-31
FI20030162A (fi) 2003-02-03
EP1136490B1 (en) 2004-01-07
CH688353A5 (de) 1997-08-15
DE69631298T2 (de) 2004-11-18
DE19603797C2 (de) 1998-11-12
HK59397A (en) 1997-05-16
AU701518B2 (en) 1999-01-28
RO112426B1 (ro) 1997-09-30
NO301009B3 (no) 2003-01-06
SI21923A (sl) 2006-06-30
CN1310180A (zh) 2001-08-29
DE69621777T2 (de) 2003-01-02
SE9600406L (sv) 1996-08-07
MX198371B (no) 2000-08-29
ATA21096A (de) 2000-08-15
BE1009112A3 (fr) 1996-11-05
IL117035A0 (en) 1996-09-12
NZ280943A (en) 1997-01-29
LV11618B (en) 1997-04-20
IE80500B1 (en) 1998-08-12
SK14396A3 (en) 1996-11-06
EP1136490A1 (en) 2001-09-26
PL312646A1 (en) 1996-08-19
CA2210022C (en) 2005-09-13
CN1216055C (zh) 2005-08-24
BR9600534A (pt) 1997-05-13
FR2730232B1 (fr) 1997-08-01
CA2211522C (en) 1999-12-07
NO960472L (no) 1996-08-07
WO1996024595A1 (en) 1996-08-15
PT101827A (pt) 1996-09-30
AU4332896A (en) 1996-08-15
NO970939D0 (no) 1997-02-28
PL189247B1 (pl) 2005-07-29
IE960104A1 (en) 1996-08-07
JP2915338B2 (ja) 1999-07-05
SE521084C2 (sv) 2003-09-30
UA49796C2 (uk) 2002-10-15
BG100333A (bg) 1996-08-30
CA2210023A1 (en) 1996-08-07
CZ297171B6 (cs) 2006-09-13
BG62967B1 (bg) 2000-12-29
OA10261A (en) 1997-09-19
TR199600096A2 (tr) 1996-08-21
CA2168829A1 (en) 1996-08-07
JPH08245620A (ja) 1996-09-24
EP0808314B1 (en) 2002-06-12
ITMI960203A0 (no) 1996-02-05
EP0808314A1 (en) 1997-11-26
AT407528B (de) 2001-04-25
SE9600406D0 (sv) 1996-02-05
NL1002248C2 (nl) 1996-09-11
SI21923B (sl) 2006-12-31
SI9600036A (en) 1996-10-31
SK283608B6 (sk) 2003-10-07
AU4786496A (en) 1996-08-27
CH689804A5 (de) 1999-11-30
AU701518C (en) 2006-12-07
LU88711A1 (fr) 1996-08-23
CN1289496C (zh) 2006-12-13
CA2211522A1 (en) 1996-08-07
KR100289885B1 (ko) 2001-05-15

Similar Documents

Publication Publication Date Title
NO970939L (no) Fremgangsmåte ved fremstilling av paroksetinhydrokloridanhydrat
NO994771D0 (no) FremgangsmÕte ved fremstilling av oligosakkarider
NO996484D0 (no) Ny fremgangsmåte for fremstilling av paroxetin faststoffdispersjon
NO20013569L (no) Fremgangsmate ved fremstilling av L-fenylephrine-hydroklorid
NO975176D0 (no) Fremgangsmåte ved fremstilling av lercanidipin-hydroklorid
NO982237D0 (no) Ny fremgangsmÕte for fremstilling av fenylimidazolidinderivater
NO975220D0 (no) Ny fremgangsmåte for fremstilling av ropivacainhydrokloridmonohydrat
NO993949L (no) FremgangsmÕte for fremstilling av substituert tiazolidindion
NO996432L (no) Fremgangsmåte for fremstilling av 4-substituert-1H-indol-3- glykosamider
NO20003145D0 (no) FremgangsmÕte for fremstilling av paroxetine-hydroklorid
NO982503D0 (no) FremgangsmÕte ved fremstilling av dioksoazabicykloheksaner
NO974846D0 (no) Fremgangsmåte for fremstilling av Form 1 Ranitidin-Hydroklorid
NO20010629D0 (no) Fremgangsmåte for fremstilling av en ikke-krystallinsk anhydratform av paroksetinhydroklorid
NO980316D0 (no) Fremgangsmåte for fremstilling av polymerisater av N-vinylkarprolaktam
NO20001793L (no) FremgangsmÕte ved fremstilling av azacykloalkylalkanoylpseudotetrapeptider
NO962809D0 (no) Fremgangsmåte for fremstilling av N-substituerte 4-ketoprolinderivater
EE200000369A (et) Isopropüülmetüül[2-(3-n-propoksüfenoksü)etüül]amiini valmistamise protsess
FI973341A0 (fi) Menetelmä organosilaanien valmistamiseksi
NO20003077D0 (no) FremgangsmÕte for fremstilling av klorbenzooksazolen
AU1396400A (en) Process for the preparation of paroxetine hydrochloride
AU6481799A (en) Process for the preparation of paroxetine hydrochloride
NO953459D0 (no) Fremgangsmåte ved fremstilling av cykloheptimidazolderivater
NO20002476D0 (no) FremgangsmÕte for fremstilling av formylimidazoler
NO994557D0 (no) Fremgangsmaate for fremstilling av arylaminotriazolopyridiner
NO964519D0 (no) Fremgangsmåte for fremstilling av chitosanalkylderivater

Legal Events

Date Code Title Description
CB Opposition filed (par. 26,5 patents act)

Opponent name: A/S GEA FARMACEUTISK FABRIK, KANALHOLMEN 8-12, DK-

Effective date: 20020829

PDP Decision of opposition (par. 25 patent act)

Free format text: PATENTET OPPRETTHOLDES I ENDRET FORM

Effective date: 20020829

MM1K Lapsed by not paying the annual fees